Immunosuppression, liver injury and post-transplant HCV recurrence

Journal of Viral Hepatitis

Volumn 19, Issue 1, 2012, Pages 1-8

  Ciesek, S ^a   Wedemeyer, H ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

antiviral treatment; hepatitis C virus; immunosuppression; liver transplantation; recurrence

Indexed keywords

ALISPORIVIR; ANTIVIRUS AGENT; AZATHIOPRINE; BOCEPREVIR; CYCLOSPORIN; CYCLOSPORIN A; ERLOTINIB; GLUCOCORTICOID; ITX 5061; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PEGINTERFERON ALPHA; RIBAVIRIN; SILIBININ; TACROLIMUS; TELAPREVIR; UNCLASSIFIED DRUG; VIRUS RNA;

DRUG EFFECT; DRUG POTENTIATION; DRUG SAFETY; GENOTYPE; GRAFT FAILURE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INFECTION PREVENTION; LIVER INJURY; LIVER TRANSPLANTATION; LONG TERM CARE; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; STEATOSIS; SURVIVAL RATE; VIRUS LOAD;

ANTIBODIES, NEUTRALIZING; ANTIVIRAL AGENTS; HEPACIVIRUS; HEPATITIS C; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-ALPHA; LIVER; LIVER TRANSPLANTATION; RECURRENCE; SILYMARIN;

EID: 84355161578     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2011.01548.x     Document Type: Review

References (80)

1. Lavanchy D,. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 2011; 17 (2): 107-115.
2. Negro F, Alberti A,. The global health burden of hepatitis C virus infection. Liver Int 2011; 31 (Suppl 2): 1-3.
3. Shepard CW, Finelli L, Alter MJ,. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5 (9): 558-567. (Pubitemid 41196755)
4. Alter MJ,. Epidemiology of hepatitis C virus infection. World J Gastroenterol 2007; 13 (17): 2436-2441. (Pubitemid 46929498)
5. Cornberg M, Razavi HA, Alberti A, et al. A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver Int 2011; 31 (Suppl 2): 30-60.
6. Kershenobich D, Razavi HA, Sanchez-Avila JF, et al. Trends and projections of hepatitis C virus epidemiology in Latin America. Liver Int 2011; 31 (Suppl 2): 18-29.
7. Simmonds P,. Genetic diversity and evolution of hepatitis C virus-15 years on. J Gen Virol 2004; 85 (Pt 11): 3173-3188. (Pubitemid 39445434)
8. Gottwein JM, Scheel TK, Jensen TB, et al. Development and characterization of hepatitis C virus genotype 1-7 cell culture systems: role of CD81 and scavenger receptor class B type I and effect of antiviral drugs. Hepatology 2009; 49 (2): 364-377.
9. Di Bisceglie AM,. Natural history of hepatitis C: its impact on clinical management. Hepatology 2000; 31 (4): 1014-1018. (Pubitemid 30169951)
10. Wiegand J, Deterding K, Cornberg M, Wedemeyer H,. Treatment of acute hepatitis C: the success of monotherapy with (pegylated) interferon alpha. J Antimicrob Chemother 2008; 62 (5): 860-865.
11. Veldt BJ, Heathcote EJ, Wedemeyer H, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 2007; 147 (10): 677-684. (Pubitemid 351664462)
12. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2011; 55 (2): 245-264.
13. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358 (9286): 958-965. (Pubitemid 32913521)
14. Manns MP, Wedemeyer H, Cornberg M,. Treating viral hepatitis C: efficacy, side effects, and complications. Gut 2006; 55 (9): 1350-1359. (Pubitemid 44277369)
15. Backus LI, Boothroyd DB, Phillips BR, Belperio P, Halloran J, Mole LA,. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol 2011; 9 (6): 509-516 e1.
16. Ciesek S, Manns MP,. Hepatitis in 2010: the dawn of a new era in HCV therapy. Nat Rev Gastroenterol Hepatol 2011; 8 (2): 69-71.
17. Dominguez-Gil B, Morales JM,. Transplantation in the patient with hepatitis C. Transpl Int 2009; 22 (12): 1117-1131.
18. Gane EJ,. The natural history of recurrent hepatitis C and what influences this. Liver Transpl 2008; 14 (Suppl 2): S36-S44.
19. Berenguer M, Prieto M, Rayon JM, et al. Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology 2000; 32 (4 Pt 1): 852-858.
20. Berenguer M,. Natural history of recurrent hepatitis C. Liver Transpl 2002; 8 (10 Suppl 1): S14-S18. (Pubitemid 35154038)
21. Berenguer M,. Host and donor risk factors before and after liver transplantation that impact HCV recurrence. Liver Transpl 2003; 9 (11): S44-S47. (Pubitemid 37408002)
22. Lai JC, Verna EC, Brown Jr RS, et al. Hepatitis C virus-infected women have a higher risk of advanced fibrosis and graft loss after liver transplantation than men. Hepatology 2011; 54 (2): 418-424.
23. Charlton M, Seaberg E, Wiesner R, et al. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology 1998; 28 (3): 823-830. (Pubitemid 28405436)
24. Humar A, Kumar D, Caliendo AM, et al. Clinical impact of human herpesvirus 6 infection after liver transplantation. Transplantation 2002; 73 (4): 599-604. (Pubitemid 34193623)
25. Belli LS, Burra P, Poli F, et al. HLA-DRB1 donor-recipient mismatch affects the outcome of hepatitis C disease recurrence after liver transplantation. Gastroenterology 2006; 130 (3): 695-702. (Pubitemid 43374520)
26. Charlton MR, Thompson A, Veldt BJ, et al. Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection. Hepatology 2011; 53 (1): 317-324.
27. Fukuhara T, Taketomi A, Motomura T, et al. Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C. Gastroenterology 2010; 139 (5): 1577-1585, 85e1-3.
28. Weston SJ, Leistikow RL, Reddy KR, et al. Reconstitution of hepatitis C virus-specific T-cell mediated immunity after liver transplantation. Hepatology 2005; 41 (1): 72-81. (Pubitemid 40068845)
29. Gruener NH, Jung MC, Ulsenheimer A, et al. Analysis of a successful HCV-specific CD8+ T cell response in patients with recurrent HCV-infection after orthotopic liver transplantation. Liver Transpl 2004; 10 (12): 1487-1496. (Pubitemid 40028381)
30. Suneetha PV, Mederacke I, Heim A, et al. Spontaneous clearance of chronic hepatitis C after liver transplantation: are hepatitis C virus-specific T cell responses the clue? Liver Transpl 2008; 14 (8): 1225-1227.
31. de Arias AE, Haworth SE, Belli LS, et al. Killer cell immunoglobulin-like receptor genotype and killer cell immunoglobulin-like receptor-human leukocyte antigen C ligand compatibility affect the severity of hepatitis C virus recurrence after liver transplantation. Liver Transpl 2009; 15 (4): 390-399.
32. Ohira M, Ishiyama K, Tanaka Y, et al. Adoptive immunotherapy with liver allograft-derived lymphocytes induces anti-HCV activity after liver transplantation in humans and humanized mice. J Clin Invest 2009; 119 (11): 3226-3235.
33. Charlton M,. Natural history of hepatitis C and outcomes following liver transplantation. Clin Liver Dis 2003; 7 (3): 585-602. (Pubitemid 37093420)
34. Park YN, Boros P, Zhang DY, Sheiner P, Kim-Schluger L, Thung SN,. Serum hepatitis C virus RNA levels and histologic findings in liver allografts with early recurrent hepatitis C. Arch Pathol Lab Med 2000; 124 (11): 1623-1627.
35. Fafi-Kremer S, Fofana I, Soulier E, et al. Viral entry and escape from antibody-mediated neutralization influence hepatitis C virus reinfection in liver transplantation. J Exp Med 2010; 207 (9): 2019-2031.
36. Lyra AC, Fan X, Lang DM, et al. Evolution of hepatitis C viral quasispecies after liver transplantation. Gastroenterology 2002; 123 (5): 1485-1493. (Pubitemid 35231648)
37. Carrion JA, Navasa M, Forns X,. Retransplantation in patients with hepatitis C recurrence after liver transplantation. J Hepatol 2010; 53 (5): 962-970.
38. Carrion JA, Martinez-Bauer E, Crespo G, et al. Antiviral therapy increases the risk of bacterial infections in HCV-infected cirrhotic patients awaiting liver transplantation: a retrospective study. J Hepatol 2009; 50 (4): 719-728.
39. Torresi J, Johnson D, Wedemeyer H,. Progress in the development of preventive and therapeutic vaccines for hepatitis C virus. J Hepatol 2011; 54 (6): 1273-1285.
40. von Hahn T, Steinmann E, Ciesek S, Pietschmann T,. Know your enemy: translating insights about the molecular biology of hepatitis C virus into novel therapeutic approaches. Expert Rev Gastroenterol Hepatol 2010; 4 (1): 63-79.
41. Meuleman P, Hesselgesser J, Paulson M, et al. Anti-CD81 antibodies can prevent a hepatitis C virus infection in vivo. Hepatology 2008; 48 (6): 1761-1768.
42. von Hahn T, Yoon JC, Alter H, et al. Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo. Gastroenterology 2007; 132 (2): 667-678. (Pubitemid 46274668)
43. Garrone P, Fluckiger AC, Mangeot PE, et al. A prime-boost strategy using virus-like particles pseudotyped for HCV proteins triggers broadly neutralizing antibodies in macaques. Sci Transl Med 2011; 3 (94): 94ra71.
44. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009; 50 (2): 227-242.
45. Syder AJ, Lee H, Zeisel MB, et al. Small molecule scavenger receptor BI antagonists are potent HCV entry inhibitors. J Hepatol 2011; 54 (1): 48-55.
46. Wagoner J, Morishima C, Graf TN, et al. Differential in vitro effects of intravenous versus oral formulations of silibinin on the HCV life cycle and inflammation. PLoS ONE 2011; 6 (1): e16464.
47. Neumann UP, Biermer M, Eurich D, Neuhaus P, Berg T,. Successful prevention of hepatitis C virus (HCV) liver graft reinfection by silibinin mono-therapy. J Hepatol 2010; 52 (6): 951-952.
48. Beinhardt S, Rasoul-Rockenschaub S, Scherzer TM, Ferenci P,. Silibinin monotherapy prevents graft infection after orthotopic liver transplantation in a patient with chronic hepatitis C. J Hepatol 2011; 54 (3): 591-592; author reply 2-3.
49. Lupberger J, Zeisel MB, Xiao F, et al. EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nat Med 2011; 17 (5): 589-595.
50. Ciesek S, von Hahn T, Colpitts CC, et al. The green tea polyphenol epigallocatechin-3-gallate (EGCG) inhibits hepatitis C virus (HCV) entry. Hepatology 2011; doi: 10.1002/hep.24610.
51. Sarrazin C, Zeuzem S,. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology 2010; 138 (2): 447-462.
52. Flisiak R, Feinman SV, Jablkowski M, et al. The cyclophilin inhibitor Debio 025 combined with PEG IFNalpha2a significantly reduces viral load in treatment-naive hepatitis C patients. Hepatology 2009; 49 (5): 1460-1468.
53. Cescon M, Grazi GL, Cucchetti A, et al. Predictors of sustained virological response after antiviral treatment for hepatitis C recurrence following liver transplantation. Liver Transpl 2009; 15 (7): 782-789.
54. Kawaoka T, Hiraga N, Takahashi S, et al. Prolongation of interferon therapy for recurrent hepatitis C after living donor liver transplantation: analysis of predictive factors of sustained virological response, including amino acid sequence of the core and NS5A regions of hepatitis C virus. Scand J Gastroenterol 2010; 45 (12): 1488-1496.
55. Rodriguez-Luna H, Vargas HE,. Management of hepatitis C virus infection in the setting of liver transplantation. Liver Transpl 2005; 11 (5): 479-489. (Pubitemid 40704057)
56. Berenguer M, Palau A, Aguilera V, Rayon JM, Juan FS, Prieto M,. Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation. Am J Transplant 2008; 8 (3): 679-687. (Pubitemid 351287553)
57. Selzner N, Guindi M, Renner EL, Berenguer M,. Immune-mediated complications of the graft in interferon-treated hepatitis C positive liver transplant recipients. J Hepatol 2011; 55 (1): 207-217.
58. Garg V, van Heeswijk R, Lee JE, Alves K, Nadkarni P, Luo X,. Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology 2011; 54 (1): 20-27.
59. Manns MP, Foster GR, Rockstroh JK, Zeuzem S, Zoulim F, Houghton M,. The way forward in HCV treatment-finding the right path. Nat Rev Drug Discov 2007; 6 (12): 991-1000. (Pubitemid 350201789)
60. Berenguer M,. [Immunosuppression and liver transplantation in patients with hepatitis C virus infection]. Gastroenterol Hepatol 2002; 25 (4): 276-279.
61. Hong JC, Kahan BD,. Immunosuppressive agents in organ transplantation: past, present, and future. Semin Nephrol 2000; 20 (2): 108-125. (Pubitemid 30158481)
62. Post DJ, Douglas DD, Mulligan DC,. Immunosuppression in liver transplantation. Liver Transpl 2005; 11 (11): 1307-1314. (Pubitemid 43071575)
63. Rifai K, Kirchner GI, Bahr MJ, et al. A new side effect of immunosuppression: high incidence of hearing impairment after liver transplantation. Liver Transpl 2006; 12 (3): 411-415.
64. Zeiser R, Nguyen VH, Beilhack A, et al. Inhibition of CD4+CD25+ regulatory T-cell function by calcineurin-dependent interleukin-2 production. Blood 2006; 108 (1): 390-399. (Pubitemid 43990654)
65. Ciesek S, Steinmann E, Wedemeyer H, et al. Cyclosporine A inhibits hepatitis C virus nonstructural protein 2 through cyclophilin A. Hepatology 2009; 50 (5): 1638-1645.
66. Ciesek S, Steinmann E, Iken M, et al. Glucocorticosteroids increase cell entry by hepatitis C virus. Gastroenterology 2010; 138 (5): 1875-1884.
67. Patel H, Heathcote EJ,. Sustained virological response with 29 days of Debio 025 monotherapy in hepatitis C virus genotype 3. Gut 2011; 60 (6): 879.
68. Berenguer M, Royuela A, Zamora J,. Immunosuppression with calcineurin inhibitors with respect to the outcome of HCV recurrence after liver transplantation: results of a meta-analysis. Liver Transpl 2007; 13 (1): 21-29. (Pubitemid 46099970)
69. Kneteman NM, Asthana S, Lewis J, et al. The impact of calcineurin inhibitors with and without interferon on HCV titers in a chimeric mouse model of HCV infection. Liver Transpl 2011; doi: 10.1002/lt.22400.
70. Sheiner PA, Schwartz ME, Mor E, et al. Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation. Hepatology 1995; 21 (1): 30-34.
71. Berenguer M,. Recurrent hepatitis C: worse outcomes established, interventions still inadequate. Liver Transpl 2007; 13 (5): 641-643. (Pubitemid 46796531)
72. Irish WD, Arcona S, Bowers D, Trotter JF,. Cyclosporine versus tacrolimus treated liver transplant recipients with chronic hepatitis C: outcomes analysis of the UNOS/OPTN database. Am J Transplant 2011; 11 (8): 1676-1685.
73. Watashi K, Hijikata M, Hosaka M, Yamaji M, Shimotohno K,. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology 2003; 38 (5): 1282-1288. (Pubitemid 37314838)
74. Selzner N, Renner EL, Selzner M, et al. Antiviral treatment of recurrent hepatitis C after liver transplantation: predictors of response and long-term outcome. Transplantation 2009; 88 (10): 1214-1221.
75. Berenguer M, Aguilera V, Prieto M, et al. Significant improvement in the outcome of HCV-infected transplant recipients by avoiding rapid steroid tapering and potent induction immunosuppression. J Hepatol 2006; 44 (4): 717-722.
76. Weiler N, Thrun I, Hoppe-Lotichius M, Zimmermann T, Kraemer I, Otto G,. Early steroid-free immunosuppression with FK506 after liver transplantation: long-term results of a prospectively randomized double-blinded trial. Transplantation 2010; 90 (12): 1562-1566.
77. Marubashi S, Dono K, Nagano H, et al. Steroid-free living donor liver transplantation in adults: impact on hepatitis C recurrence. Clin Transplant 2009; 23 (6): 904-913.
78. Sgourakis G, Radtke A, Fouzas I, et al. Corticosteroid-free immunosuppression in liver transplantation: a meta-analysis and meta-regression of outcomes. Transpl Int 2009; 22 (9): 892-905.
79. Llado L, Fabregat J, Castellote J, et al. Impact of immunosuppression without steroids on rejection and hepatitis C virus evolution after liver transplantation: results of a prospective randomized study. Liver Transpl 2008; 14 (12): 1752-1760.
80. Vivarelli M, Burra P, La Barba G, et al. Influence of steroids on HCV recurrence after liver transplantation: a prospective study. J Hepatol 2007; 47 (6): 793-798. (Pubitemid 350051119)